Published in Biochim Biophys Acta on January 18, 1993
Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med (1982) 4.05
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (2001) 3.64
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1992) 2.76
Managing oral anticoagulant therapy. Chest (2001) 2.25
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1998) 2.17
Management of heparin therapy: Controlled prospective trial. N Engl J Med (1975) 2.07
Activation of phospholipases A2 and C in pig aortic endothelial cells synthesizing prostacyclin. J Biol Chem (1982) 1.67
Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest (1990) 1.44
Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol (1985) 1.38
Platelet size as a determinant of platelet function. J Lab Clin Med (1983) 1.37
The activation by Ca2+ of platelet phospholipase A2. Effects of dibutyryl cyclic adenosine monophosphate and 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate. Biochim Biophys Acta (1978) 1.35
Ethanol potentiation of aspirin-induced prolongation of the bleeding time. N Engl J Med (1982) 1.35
Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med (1980) 1.32
Arachidonic acid metabolism by platelets of differing size. Br J Haematol (1983) 1.29
Mobilization of arachidonic acid in human platelets. Kinetics and Ca2+ dependency. Biochim Biophys Acta (1977) 1.27
Clinical trial of a new bleeding-time device. Am J Clin Pathol (1978) 1.26
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1995) 1.24
The incorporation of acetate and palmitate into lipids by human platelets. J Clin Invest (1968) 1.24
Platelet size and age determine platelet function independently. Blood (1984) 1.22
The activation of phosphatidylinositol-hydrolyzing phospholipase A2 during prostaglandin synthesis in transformed mouse BALB/3T3 cells. J Biol Chem (1981) 1.20
Evidence for a structural requirement for the aggregation of platelets by collagen. J Clin Invest (1974) 1.19
The clinical challenge of disseminated intravascular coagulation. N Engl J Med (1970) 1.16
Transfer of arachidonic acid to human platelet plasmalogen in response to thrombin. Biochem Biophys Res Commun (1976) 1.15
Cooperative studies in health services research in the Department of Veterans Affairs. Control Clin Trials (1998) 1.14
Arachidonoyl transacylase in human platelets. Coenzyme A-independent transfer of arachidonate from phosphatidylcholine to lysoplasmenylethanolamine. J Biol Chem (1983) 1.13
The mobilization of arachidonic acid in platelets exposed to thrombin or ionophore A23187. Effects of adenosine triphosphate deprivation. J Clin Invest (1977) 1.12
The natural history of endothelial structure and function in arterialized vein grafts. J Vasc Surg (1986) 1.11
The assessment of drug-dependent and isoimmune antiplatelet antibodies by the use of platelet aggregometry. J Clin Invest (1972) 1.11
The effect of thrombin on the uptake and transformation of arachidonic acid by human platelets. Am J Hematol (1976) 1.10
Favorable balance of prostacyclin and thromboxane A2 improves early patency of human in situ vein grafts. J Vasc Surg (1984) 1.07
Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate. Blood (1979) 1.06
Metabolism of platelet-activating factor in human platelets. Transacylase-mediated synthesis of 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. J Biol Chem (1984) 1.05
Current concepts: the use of heparin. N Engl J Med (1969) 1.05
Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (1995) 1.05
Isolation of membranes from normal and thrombin-treated gel-filtered platelets using a lectin marker. Biochim Biophys Acta (1976) 1.05
Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1992) 1.04
Hepatic removal of activated factor X by the perfused rabbit liver. Am J Physiol (1968) 1.01
Solubilization and properties of Ca2+-dependent human platelet phospholipase A2. Biochim Biophys Acta (1986) 1.00
Warfarin therapy. 1. N Engl J Med (1970) 1.00
Plasma co-factors in adenosine diphosphate-induced aggregation of human platelets. Nature (1965) 0.97
Effect of epinephrine on platelet lipid metabolism. J Lab Clin Med (1973) 0.96
Thrombogenesis. N Engl J Med (1967) 0.95
Stimulation of Ca2+-activated human platelet phospholipase A2 by diacylglycerol. Biochem J (1987) 0.94
The role of the liver in serum-induced hypercoagulability. J Clin Invest (1966) 0.94
Optimal therapeutic range for oral anticoagulants. Chest (1989) 0.92
Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood. Am J Med (1986) 0.92
Coenzyme A-mediated arachidonic acid transacylation in human platelets. J Biol Chem (1984) 0.92
Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma. Proc Natl Acad Sci U S A (1981) 0.92
Tranylcypromine and 15-hydroperoxyarachidonate affect arachidonic acid release in addition to inhibition of prostacyclin synthesis in calf aortic endothelial cells. J Biol Chem (1980) 0.92
Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction. J Lab Clin Med (1985) 0.91
Methods for the separation of platelets from plasma. A comparison of functional and morphological integrity. Thromb Diath Haemorrh (1974) 0.91
"Therapeutic range" for oral anticoagulant therapy. Chest (1986) 0.90
Uremic bleeding. Kidney Int (1983) 0.90
Specificity of phospholipases in methylcholanthrene-transformed mouse fibroblasts activated by bradykinin, thrombin, serum, and ionophore A23187. J Biol Chem (1979) 0.88
Incorporation and redistribution of arachidonic acid in diacyl and ether phospholipids of bovine aortic endothelial cells. Biochim Biophys Acta (1986) 0.88
The spectrum of vitamin K deficiency. JAMA (1977) 0.88
Ionophore-induced metabolism of phospholipids and eicosanoid production in porcine aortic endothelial cells: selective release of arachidonic acid from diacyl and ether phospholipids. Biochim Biophys Acta (1987) 0.88
Heparin-induced thrombocytopenia and recurrent thromboembolism. Am J Hematol (1980) 0.87
Quantitative determination of factor-VIII protein by two-stage gel electrophoresis. Br J Haematol (1976) 0.87
Elevated glucose alters eicosanoid release from porcine aortic endothelial cells. J Clin Invest (1988) 0.86
Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2. Biochim Biophys Acta (1988) 0.86
Arachidonic acid level in cellular lipids determines the amount of prostaglandins synthesized during cell growth in tissue culture. Prostaglandins (1979) 0.85
Platelet dysfunction in glycogen storage disease type I. Blood (1973) 0.85
The bleeding time response to aspirin. Identifying the hyperresponder. Am J Clin Pathol (1990) 0.85
Issues in the early termination of the aspirin component of the Physicians' Health Study. Data Monitoring Board of the Physicians' Health Study. Ann Epidemiol (1991) 0.85
The Ponte Vedra syndrome--an unexpected interaction between alcohol and aspirin. Trans Am Clin Climatol Assoc (1982) 0.85
Emerging concepts of platelet function. N Engl J Med (1974) 0.85
Efficacy and safety of combined anticoagulant and antiplatelet therapy versus anticoagulant monotherapy after mechanical heart-valve replacement: a metaanalysis. Am Heart J (1995) 0.83
The use of high pressure liquid chromatography (HPLC) for the separation of radiolabeled arachidonic acid and its metabolities produced by thrombin-treated human platelets. I. The validation of the technique. Prostaglandins (1979) 0.83
Effects of insulin and prior exercise on prostaglandin release from perfused rat muscle. Evidence that prostaglandins do not mediate changes in glucose uptake. Biochem J (1986) 0.82
In vivo dissociation of factor VII (AHF) activity and factor VII-related antigen in von Willebrand's disease. Am J Hematol (1976) 0.82
Effect of membrane cholesterol on phospholipid metabolism in thrombin-stimulated platelets. Enhanced activation of platelet phospholipase(s) for liberation of arachidonic acid. J Biol Chem (1982) 0.81
A chlorpromazine-induced inhibitor of blood coagulation. Am J Hematol (1977) 0.81
Warfarin therapy. 2. N Engl J Med (1970) 0.81
Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J Lab Clin Med (1986) 0.81
Current status of anticoagulant therapy. Am J Med (1982) 0.79
Hepatic transport and secretion of unesterified cholesterol in the rat is traced by the plant sterol, sitostanol. J Lipid Res (1996) 0.79
An hepatic inhibitor of activated clotting factor X (Stuart). Biochem Biophys Res Commun (1969) 0.79
A state-of-the-art conference on databases pertaining to veterans' health. A resource for research and decision making. Med Care (1996) 0.79
Passage state affects arachidonic acid content and eicosanoid release in porcine aortic endothelial cells. Arterioscler Thromb (1991) 0.79
Intermediate syndrome of platelet dysfunction. Blood (1978) 0.79
Interaction of ethanol, prostacyclin, and aspirin in determining human platelet reactivity in vitro. Arteriosclerosis (1988) 0.79
The use of high pressure liquid chromatography (HPLC) for the separation of radiolabeled arachidonic acid and its metabolites produced by thrombin-treated human platelets. II. Establishment of optimal assay conditions. Prostaglandins (1979) 0.79
Antithrombotic therapy. Rationale and application. Postgrad Med (1979) 0.78
A computer-based teaching program in hemostasis. Blood (1972) 0.77
Neointimal hyperplasia occurring after carotid endarterectomy in a canine model: effect of endothelial cell seeding vs. perioperative aspirin. J Vasc Surg (1987) 0.77
Diurnal changes and adaptation by the liver of hamsters to an atherogenic diet. Am J Physiol (1995) 0.77
Low solubility fibrinogen examined by two-dimensional sodium dodecyl sulfate gel electrophoresis and isoelectric focusing. Thromb Res (1978) 0.77
Altered arachidonic acid metabolism and platelet size in atopic subjects. Clin Immunol Immunopathol (1988) 0.77
Detection of intracoronary fibrin degradation after coronary balloon angioplasty. Am J Cardiol (1991) 0.76
Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels. Am J Clin Nutr (1988) 0.76
Hepatitis after Konyne administration. N Engl J Med (1971) 0.76
Abnormal factor VIII coagulant antigen in patients with renal dysfunction and in those with disseminated intravascular coagulation. J Clin Invest (1985) 0.75
Local and systemic factors in the pathogenesis of thrombosis. Calif Med (1970) 0.75